A Brown University-led study has linked at least one dose of the recombinant shingles vaccine Shingrix to a 24% lower relative risk of dementia over four years in older adults admitted to skilled nursing facilities. The finding, published in The Annals of Internal Medicine, does not show that the vaccine prevents dementia, but it adds to a growing body of research suggesting the shot may be associated with broader health benefits than shingles protection alone.
The study examined electronic health records and Medicare claims for more than 509,926 U.S. adults 66 and older. People who received Shingrix had lower dementia risk than those who did not, a pattern that has drawn attention because the vaccine is already widely used to prevent painful shingles reactivations and long-term nerve damage. For readers searching now, the reason is simple: this is a new, large-scale finding involving a familiar vaccine and a disease that touches millions of families.
Ajeet Sodhi called the result “remarkable,” saying this was “maybe the third or fourth study” to point in the same direction. He said the pattern suggests that “by giving patients the shingles vaccine called Shingrix, in the next couple of years, we see a clinically significant decline in the development of dementia.” Even so, he was clear about the limit of the evidence. “It’s not at this time considered a treatment,” he said, adding that the association is “very, very suggestive, but we can’t say one-to-one it proves that this treats dementia.”
The researchers offered a possible explanation: preventing shingles and the complications that can follow may help lower downstream risk. The virus has been linked to vascular events such as stroke, which can contribute to vascular dementia. That does not settle the question of how, or whether, Shingrix affects dementia risk directly. It only shows that in a very large group of older adults, the vaccinated group did better over time.
Sodhi also pointed to a separate study published this week that found the shingles vaccine was associated with a clinically significant reduction in cardiovascular disease and cerebrovascular disease. Taken together, the findings make the shot look less like a one-purpose vaccine and more like a tool with possible ripple effects on aging health. But the main fact remains the same: the evidence is associative, not causal, and the next step is not treatment but more research to explain why the signal keeps appearing. For now, Shingrix remains what the FDA approved it to be — a vaccine against shingles and its complications — with dementia benefit still an intriguing question rather than a medical claim.
